Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Alberto Ortíz(Universidad Pontificia de Salamanca), David G. Warnock(University of Alabama at Birmingham), Manesh R. Patel(Duke University), Robert J. Hopkin(Cincinnati Children's Hospital Medical Center), João Paulo Oliveira(Universidade do Porto), Christoph Wanner(Universitätsklinikum Würzburg), Ana Jovanović(Manchester Academic Health Science Centre), Dominique P. Germain(Assistance Publique – Hôpitaux de Paris), Aleš Linhart(Charles University), Ademola K. Abiose(Ohio Heart & Vascular Center), Gustavo Cabrera, Juan Politei(Development Fund), Daniel G. Bichet(Hôpital du Sacré-Cœur de Montréal), Stephen Waldek, Sonia S. Maruti, Michael Mauer(University of Minnesota), Joel Charrow(Northwestern University), Han‐Wook Yoo(CHA University Bundang Medical Center)
Cited by 147
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
Global vascular guidelines on the management of chronic limb-threatening ischemia
|Journal of Vascular Surgery|2019|1.9k
Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia
|European Journal of Vascular and Endovascular Surgery|2019|1.5k